Lumiracoxib

From Wikipedia, the free encyclopedia


Lumiracoxib
Systematic (IUPAC) name
{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl} acetic acid
Identifiers
CAS number	?
ATC code	M01 AH06
PubChem	151166
Chemical data
Formula	C₁₅H₁₃N Cl F O₂
Mol. weight	293.72 g/mol
Pharmacokinetic data
Bioavailability	74% (oral)
Protein binding	>98%
Metabolism	Hepatic oxidation and hydroxylation (CYP2C9)
Half life	4 hours
Excretion	Renal and fecal
Therapeutic considerations
Pregnancy cat.	C(AU)
Legal status	POM (UK) Red Stripe (Brazil)
Routes	Oral

Lumiracoxib (rINN) is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and sold in 21 countries, including the United Kingdom, Australia, Argentina and Brazil, under the trade name Prexige® (sometimes misquoted as "Prestige" by the media). The Therapeutic Arthritis Research and Gastrointestinal Event Trial was conducted to test its gastrointestinal and cardiovascualr safety against Naproxen and Ibuprofen and also study its efficacy against these two NSAIDs. As of 2006, the Food and Drug Administration (FDA) has not yet granted approval for its sale in the United States.

Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac, making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.